Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Corinne Bott-Silverman, MD, is a staff cardiologist in the Cleveland Clinic Department of Cardiology, Section of Heart Failure and Transplant Center in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic. She is board-certified in internal medicine and cardiovascular disease. Dr. Bott-Silverman’s specialty interests include heart failure, heart transplantation, clinical cardiology, myocardial biopsy and cardiac catheterization.
Dr. Bott-Silverman did her undergraduate work in biology, graduating summa cum laude from Washington University. She received her medical degree from St. Louis University School of Medicine, graduating cum laude. She completed her internship and residency in internal medicine at Cleveland Clinic, where she was offered a fellowship to pursue additional clinical training in invasive cardiology. She was appointed to the Cleveland Clinic staff in 1986.
She has authored or co-authored numerous peer-reviewed articles published in leading medical journals, among them Circulation, the American Heart Journal, Journal of Cardiac Failure, Journal of the American College of Cardiology, and the American Journal of Transplantation. Her articles have examined a wide variety of topics related to heart failure, angiography and vasculopathy. In 2003, she provided a chapter in a medical online textbook on dilated and restrictive cardiomyopathies. A recent book chapter contribution is "Dilated and Restrictive Cardiomyopathies in the Cleveland Clinic: Current Clinical Medicine."
Dr. Bott-Silverman is a Fellow in the American College of Cardiology and in the Society for Cardiac Angiography and Intervention. She is a recipient of the Cleveland Clinic Foundation Cardiology Research Award.
Cardiomyopathy, cardiac tumors, heart failure, heart transplantation, ventricular assist device, myocardial biopsy, cardiac catheterization
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/1/2015, Dr. Bott-Silverman has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.